AstraZeneca To Invest $50 Billion In The U.S. To Expand Medicines Manufacturing And R&D Capabilities

AstraZeneca has announced plans to invest $50 billion in the United States by 2030, marking a major expansion of its research, development, and manufacturing presence in the country. This substantial investment is expected to generate tens of thousands of direct and indirect jobs across the U.S., supporting the development and delivery of next-generation medicines for both American patients and global populations. The initiative builds on the country’s leadership in life sciences and reinforces AstraZeneca’s long-term commitment to advancing medical innovation in the U.S.

At the heart of this investment is a new multi-billion dollar manufacturing facility planned for the Commonwealth of Virginia. This site will focus on producing drug substances for AstraZeneca’s pipeline of weight management and metabolic treatments, including oral GLP-1 therapies, baxdrostat, oral PCSK9 inhibitors, and combination small molecule products. The facility will be capable of manufacturing small molecules, peptides, and oligonucleotides and will be AstraZeneca’s largest single manufacturing investment globally. It will use cutting-edge technologies such as artificial intelligence, automation, and data analytics to optimize production processes

Howard Lutnick, US Secretary of Commerce, said in a statement, “For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation’s new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.”

Governor Glenn Youngkin, Commonwealth of Virginia, stated, “I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth.”

Pascal Soriot, Chief Executive Officer, AstraZeneca, mentioned, “Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia’s desire to create highly skilled jobs in science and technology, and will strengthen the country’s domestic supply chain for medicines.”

In addition to this flagship facility, AstraZeneca’s $50 billion investment plan includes several other major projects across the country. These include the expansion of the R&D facility in Gaithersburg, Maryland; the development of a state-of-the-art R&D center in Kendall Square, Cambridge, Massachusetts; and the establishment of next-generation cell therapy manufacturing facilities in Rockville, Maryland, and Tarzana, California. 

The company also plans to grow its continuous manufacturing capabilities in Mount Vernon, Indiana, and expand specialty manufacturing operations in Coppell, Texas. New sites will also be developed to support clinical trials and further boost AstraZeneca’s pipeline of innovative medicines. These efforts align with AstraZeneca’s strategic goal of achieving $80 billion in total revenue by 2030, with half of that expected to come from the U.S. market. The combined investments across manufacturing and research centers reflect the company’s focus on advancing science, enhancing supply chain resilience, and delivering transformative therapies to patients worldwide.